• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Emergent BioSolutions Expands Its Baltimore, Maryland, Manufacturing Hub

Emergent BioSolutions, a global specialty biopharmaceutical company, is expanding its manufacturing facility on Lombard Street in Baltimore, Maryland. The expansion is slated to potentially double the company’s 58,000 square-foot space to include additional manufacturing, quality control labs and warehouse space, and is expected to add 158 new jobs over the next four years.

“Emergent BioSolutions’ expansion in Baltimore City is great news and underscores our commitment to biotechnology manufacturing and to our rich research and development environment,” said Baltimore Development Corporation President/CEO William H. Cole. “In 2009, BDC facilitated the sale of city-owned land to Emergent on which its facility sits; and in 2014, we assisted the company in acquiring additional property for its expansion. I am proud that BDC has played a pivotal role in Emergent’s continuing growth and in job creation for the city’s bioscience and manufacturing sectors.”

The State is supporting Emergent’s expansion through a previously approved $2 million conditional loan from DBED’s Maryland Economic Development Assistance Authority and Fund. The loan was offered to help start this two-phase project—phase one supported the relocation and expansion of the company’s headquarters and research and development site in Gaithersburg, as well as the anticipated addition of 133 new employees.

“Emergent has enjoyed considerable growth since first establishing its headquarters in Maryland over a decade ago,” said Daniel J. Abdun-Nabi, President/CEO of Emergent BioSolutions. “We are pleased to continue to expand our footprint and remain committed to making Maryland one of the most vibrant life sciences hubs in the country. We thank the state and local governments for fostering economic initiatives to support companies such as Emergent in its mission of protecting and enhancing life.”

“Emergent Biosolutions’ decision to continue to invest in our State means more jobs and more opportunities for Marylanders,” said Maryland Department of Business & Economic Development Secretary Mike Gill. “The company’s recent expansion of its headquarters in Gaithersburg combined with this expansion project is expected to create close to 300 new jobs and helps solidify Maryland’s position as a life sciences powerhouse.”

In a cost-sharing contract awarded to Emergent in 2012, the U.S. Department of Health and Human Services committed $222 million to establish Emergent’s Baltimore facility as a Center for Innovation in Advanced Development and Manufacturing to facilitate advanced development of medical countermeasures and provide domestic surge manufacturing capabilities to address public health threats. Recently, Emergent was one of the companies tapped by the Biomedical Advanced Research and Development Authority to investigate producing ZMapp, an experimental drug for Ebola. The company also manufactures BioThrax, Anthrax Vaccine Adsorbed, the only FDA-licensed vaccine for the prevention of anthrax disease.

Article Discussion

Follow Area Development